293 related articles for article (PubMed ID: 9442107)
21. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
Finnegan CM; Berg W; Lewis GK; DeVico AL
J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
[TBL] [Abstract][Full Text] [Related]
22. An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120.
Alam SM; Paleos CA; Liao HX; Scearce R; Robinson J; Haynes BF
AIDS Res Hum Retroviruses; 2004 Aug; 20(8):836-45. PubMed ID: 15320988
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
24. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
Kliger Y; Shai Y
J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
[TBL] [Abstract][Full Text] [Related]
26. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
[TBL] [Abstract][Full Text] [Related]
27. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor.
Su SB; Gong WH; Gao JL; Shen WP; Grimm MC; Deng X; Murphy PM; Oppenheim JJ; Wang JM
Blood; 1999 Jun; 93(11):3885-92. PubMed ID: 10339497
[TBL] [Abstract][Full Text] [Related]
28. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion.
Pritsker M; Jones P; Blumenthal R; Shai Y
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7287-92. PubMed ID: 9636141
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S
Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358
[TBL] [Abstract][Full Text] [Related]
30. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
31. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
32. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
[TBL] [Abstract][Full Text] [Related]
33. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
34. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion.
Muñoz-Barroso I; Salzwedel K; Hunter E; Blumenthal R
J Virol; 1999 Jul; 73(7):6089-92. PubMed ID: 10364363
[TBL] [Abstract][Full Text] [Related]
35. Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction.
Dimitrov DS; Broder CC; Berger EA; Blumenthal R
J Virol; 1993 Mar; 67(3):1647-52. PubMed ID: 8437234
[TBL] [Abstract][Full Text] [Related]
36. Temperature dependence of cell-cell fusion induced by the envelope glycoprotein of human immunodeficiency virus type 1.
Frey S; Marsh M; Günther S; Pelchen-Matthews A; Stephens P; Ortlepp S; Stegmann T
J Virol; 1995 Mar; 69(3):1462-72. PubMed ID: 7853478
[TBL] [Abstract][Full Text] [Related]
37. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.
Chen CH; Matthews TJ; McDanal CB; Bolognesi DP; Greenberg ML
J Virol; 1995 Jun; 69(6):3771-7. PubMed ID: 7538176
[TBL] [Abstract][Full Text] [Related]
38. Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.
Verrier FC; Charneau P; Altmeyer R; Laurent S; Borman AM; Girard M
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9326-31. PubMed ID: 9256481
[TBL] [Abstract][Full Text] [Related]
39. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
40. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
